[1] ETTINGER J, PATEL A, OHRNBERGER J, et al. Exploration of preferences among people with COPD to inform resource allocation: a discrete choice experiment study[J]. BMJ Open Respir Res, 2024, 11(1): e001914. doi:  10.1136/bmjresp-2023-001914
[2] PAIGE S R, KRIEGER J L, WILLIAMS M, et al. Patient message preferences to promote clinical conversations about chronic obstructive pulmonary disease(COPD): a discrete choice experiment[J]. PEC Innov, 2023, 2: 100168. doi:  10.1016/j.pecinn.2023.100168
[3] BØGELUND M, HAGELUND L, ASMUSSEN M B. COPD-treating nurses’ preferences for inhaler attributes–a discrete choice experiment[J]. Curr Med Res Opin, 2017, 33(1): 71-75. doi:  10.1080/03007995.2016.1238353
[4] 邵家琛, 李顺平, 杨汀, 等. 利用离散选择试验测量慢性阻塞性肺疾病患者治疗与装置偏好的综述[J]. 中国全科医学, 2025, 28(36): 4648-4654.
[5] HAWKEN N, TORVINEN S, NEINE M E, et al. Patient preferences for dry powder inhaler attributes in asthma and chronic obstructive pulmonary disease in France: a discrete choice experiment[J]. BMC Pulm Med, 2017, 17(1): 99. doi:  10.1186/s12890-017-0439-x
[6] SCHROEDER M, HALL K, ELIASSON L, et al. Treatment preferences of patients with chronic obstructive pulmonary disease: results from qualitative interviews and focus groups in the United Kingdom, United States, and Germany[J]. Chronic Obstr Pulm Dis, 2021, 8(1): 19-30. doi:  10.15326/jcopdf.8.1.2020.0131
[7] KAWATA A K, KLEINMAN L, HARDING G, et al. Evaluation of patient preference and willingness to pay for attributes of maintenance medication for chronic obstructive pulmonary disease(COPD)[J]. Patient Patient Centered Outcomes Res, 2014, 7(4): 413-426. doi:  10.1007/s40271-014-0064-1
[8] LIU S N, WU T T, YU Y, et al. Patients’ preferences regarding traditional Chinese medicine for the treatment of chronic obstructive pulmonary disease: protocol for a mixed methods study[J]. JMIR Res Protoc, 2025, 14: e75426. doi:  10.2196/75426
[9] Global Initiative for Chronic Obstructive Lung Disease. Global strategy for prevention, diagnosis and management of COPD: 2025 report[EB/OL].(2024-11-15)[2026-03-06]. https://goldcopd.org/2025-gold-report/.
[10] 基本公共卫生服务项目基层慢阻肺病防治管理办公室, 国家慢性呼吸疾病防治办公室, 国家呼吸医学中心, 等. 国家基层慢性阻塞性肺疾病防治及管理实施指南(2025)[J]. 中华全科医师杂志, 2026, 25(1): 6-24.
[11] 国务院. 国务院关于徐州市城市总体规划的批复[EB/OL]. (2017-06-16)[2026-04-13]. 中国政府网. https://app.www.gov.cn/govdata/gov/201706/23/406911/article.html.
[12] 国家发展改革委. 江苏徐州产业转型升级示范区建设方案[EB/OL].(2020-04-01)[2026-04-13]. 国家发展改革委. https://www.ndrc.gov.cn/fzggw/jgsj/zxs/sjdt.
[13] Liu W, Ling X, Xue Y, et al. Study on the concentration of top air pollutants in Xuzhou City in winter 2020 based on the WRF-Chem and ADMS-Urban models[J]. Atmosphere, 2024, 15: 129. doi:  10.3390/atmos15010129
[14] LOU P A, ZHU Y N, CHEN P P, et al. Vulnerability, beliefs, treatments and economic burden of chronic obstructive pulmonary disease in rural areas in China: a cross-sectional study[J]. BMC Public Health, 2012, 12(1): 287. doi:  10.1186/1471-2458-12-287
[15] KRUCIEN N, LE VAILLANT M, PELLETIER-FLEURY N. What are the patients' preferences for the Chronic Care Model? An application to the obstructive sleep apnoea syndrome[J]. Health Expect, 2015, 18(6): 2536-2548. doi:  10.1111/hex.12222
[16] LEWIS H B, SCHROEDER M, GUNSOY N B, et al. Evaluating patient preferences of maintenance therapy for the treatment of chronic obstructive pulmonary disease: a discrete choice experiment in the UK, USA and Germany[J]. Int J Chronic Obstr Pulm Dis, 2020, 15: 595-604. doi:  10.2147/COPD.S221980
[17] TERVONEN T, HAWKEN N, HANANIA N A, et al. Maintenance inhaler therapy preferences of patients with asthma or chronic obstructive pulmonary disease: a discrete choice experiment[J]. Thorax, 2020, 75(9): 735-743. doi:  10.1136/thoraxjnl-2019-213974
[18] PISA G, FREYTAG S, SCHANDRY R. Chronic obstructive pulmonary disease(COPD)patients’ disease-related preferences[J]. Patient Patient Centered Outcomes Res, 2013, 6(2): 93-101.
[19] RATCLIFFE J, VAN HASELEN R, BUXTON M, et al. Assessing patients' preferences for characteristics associated with homeopathic and conventional treatment of asthma: a conjoint analysis study[J]. Thorax, 2002, 57(6): 503-508. doi:  10.1136/thorax.57.6.503
[20] GREEN C, GERARD K. Exploring the social value of health-care interventions: a stated preference discrete choice experiment[J]. Health Econ, 2009, 18(8): 951-976. doi:  10.1002/hec.1414
[21] LANCSAR E, LOUVIERE J. Conducting discrete choice experiments to inform healthcare decision making[J]. PharmacoEconomics, 2008, 26(8): 661-677. doi:  10.2165/00019053-200826080-00004
[22] PEARMAIN D, SWANSON J, KROES E. Stated preference techniques: a guide to practice[M]. 2nd ed. The Hague: Steer Davies Gleave and Hague Consulting Group, 1991.
[23] MIRAVITLLES M, AULADELL-RISPAU A, MONTEAGUDO M, et al. Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD[J]. Eur Respir Rev, 2021, 30(160): 210075. doi:  10.1183/16000617.0075-2021
[24] FESTIC E, BANSAL V, GUPTA E, et al. Association of inhaled corticosteroids with incident pneumonia and mortality in COPD patients; systematic review and meta-analysis[J]. COPD J Chronic Obstr Pulm Dis, 2016, 13(3): 312-326. doi:  10.3109/15412555.2015.1081162
[25] BHATT SP, DRANSFIELD MT, COCKCROFT JR, et al. A randomized trial of once-daily fluticasone furoate/vilanterol or vilanterol versus placebo to determine effects on arterial stiffness in COPD[J]. Int J Chron Obstruct Pulmon Dis, 2017, 12: 351-365. doi:  10.2147/COPD.S117373
[26] SALPETER S R, BUCKLEY N S. Systematic review of clinical outcomes in chronic obstructive pulmonary disease: β-agonist use compared with anticholinergics and inhaled corticosteroids[J]. Clin Rev Allergy Immunol, 2006, 31(2-3): 219-230. doi:  10.1385/CRIAI:31:2:219
[27] TASHKIN DP, CELLI B, SENN S, BURKHART D, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease[J]. N Engl J Med, 2008, 359(15): 1543-1554. doi:  10.1056/NEJMoa0805800
[28] RESTREPO R D, ALVAREZ M T, WITTNEBEL L D, et al. Medication adherence issues in patients treated for COPD[J]. Int J Chron Obstruct Pulmon Dis, 2008, 3(3): 371-384. doi:  10.2147/copd.s3036
[29] BHATTARAI B, WALPOLA R, MEY A, et al. Barriers and strategies for improving medication adherence among people living with COPD: a systematic review[J]. Respir Care, 2020, 65(11): 1738-1750. doi:  10.4187/respcare.07355
[30] CHEN X, GONG D, HUANG H, et al. Expert consensus and operational guidelines on exercise rehabilitation of chronic obstructive pulmonary disease with integrating traditional Chinese medicine and Western medicine[J]. J Thorac Dis, 2021, 13(6): 3323-3346. doi:  10.21037/jtd-21-431
[31] 冯于洛, 王雅葳, 褚燕琦, 等. 临床药师床旁教育实践及患者依从性评价[J]. 药学实践杂志, 2018, 36(6): 554-556,560.
[32] LOPEZ-CAMPOS J L, CALERO C, QUINTANA-GALLEGO E. Symptom variability in COPD: a narrative review[J]. Int J Chronic Obstr Pulm Dis, 2013, 8: 231-238. doi:  10.2147/copd.s42866
[33] 2023年徐州市国民经济和社会发展统计公报[EB/OL]. 2024-04-22[2026-04-13]. https://www.tjnj.net/newsview/20250330211357.
[34] 徐州市调整城乡居民基本医疗保险筹资标准[EB/OL]. 2023-10-30[2026-04-13]. https://www.zgjssw.gov.cn/shixianchuanzhen/xuzhou/202310/t20231030_8137037.shtml.
[35] TOY E L, BEAULIEU N U, MCHALE J M, et al. Treatment of COPD: Relationships between daily dosing frequency, adherence, resource use, and costs[J]. Respir Med, 2011, 105(3): 435-441. doi:  10.1016/j.rmed.2010.09.006
[36] MILNE K M, MITCHELL R A, FERGUSON O N, et al. Sex-differences in COPD: from biological mechanisms to therapeutic considerations[J]. Front Med, 2024, 11: 1289259. doi:  10.3389/fmed.2024.1289259
[37] LEE H, JUNG J, YOON H Y. Impact of socioeconomic status on chronic obstructive pulmonary disease prognosis: a national cohort study[J]. Front Med, 2025, 12: 1584945. doi:  10.3389/fmed.2025.1584945
[38] NIELSEN A O, LANGE P, HILBERG O, et al. COPD and smoking status–it does matter: characteristics and prognosis of COPD according to smoking status[J]. Chronic Obstr Pulm Dis J COPD Found, 2024, 11(1): 56-67. doi:  10.15326/jcopdf.2023.0433
[39] KAHNERT K, JÖRRES R A, BEHR J, et al. The diagnosis and treatment of COPD and its comorbidities[J]. Deutsches Ärzteblatt Int. 2023: 120(25): 434-444.
[40] 段虎, 周艳卿, 钱瑜琳, 等. 某二级医院稳定期慢性阻塞性肺疾病患者吸入治疗依从性及其影响因素[J]. 药学实践与服务, 2025, 43(07): 362-366. doi:  10.12206/j.issn.2097-2024.202204094
[41] MATERA M G, HANANIA N A, MANISCALCO M, et al. Pharmacotherapies in older adults with COPD: challenges and opportunities[J]. Drugs Aging, 2023, 40(7): 605-619. doi:  10.1007/s40266-023-01038-0
[42] O’CONOR R, MUELLERS K, ARVANITIS M, et al. Effects of health literacy and cognitive abilities on COPD self-management behaviors: a prospective cohort study[J]. Respir Med, 2019, 160: 105630. doi:  10.1016/j.rmed.2019.02.006
[43] 蔡建, 李明明, 张平, 等. 门诊抑郁患者的药物品牌偏好及对用药依从性和疗效的影响[J]. 药学实践杂志, 2017, 35(02): 154-157+164+181. doi:  10.3969/j.issn.1006-0111.2017.02.014
[44] 陈丹, 刘国栋, 刘煜, 等. 咳喘医药联合门诊服务模式的实践与探索[J]. 药学实践与服务, 2023, 41(11): 689-693. doi:  10.12206/j.issn.2097-2024.202209034